Bain Capital Life Sciences Investors, LLC is 10% Owner at MARINUS PHARMACEUTICALS INC (MRNS). They have made 8 open-market trades across 7 companies since 2017, most recently 2026-05-20.
CIK 0001703031
5 open-market purchases totalling $36.9M since 2018, against 3 sales. Across 5 scored buys the stock is down 16.8% at ninety days, and 16.8 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 80% | 60% | 20% |
| Avg Move | +5.0% | +1.7% | -16.8% |
| Alpha | +3.2% | -1.6% | -16.8% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| HTFL | SELL | 2026-04-28 | 2026-04-30 | $29.45 | $58.9M | -0.5% | +4.6% | -15.4% |
| KLRA | BUY | 2026-04-20 | 2026-04-20 | $16.00 | $25.0M | +0.6% | -19.3% | -28.0% |
| HTFL | SELL | 2026-02-04 | 2026-02-06 | $28.05 | $56.1M | -13.5% | -16.5% | +8.0% |
| OLMA | BUY | 2025-01-08 | 2025-01-13 | $5.76 | $1.7M | +9.4% | -9.2% | -25.4% |
| ANNX | BUY | 2023-05-25 | 2023-05-30 | $2.13 | $639K | -3.1% | +17.6% | +2.8% |
| RPID | BUY | 2021-07-19 | 2021-07-21 | $20.00 | $2.0M | +13.0% | +7.3% | -11.7% |
| REPL | BUY | 2018-07-24 | 2018-07-26 | $15.00 | $7.5M | +5.3% | +12.0% | -21.9% |
| MRNS | SELL | 2017-12-15 | 2017-12-19 | $7.93 | $17.8M | +11.7% | -8.5% | -45.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| Total | $737.8M |
Shares reported on the most recent Form 4, priced at the 2026-05-22 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.